Decision analysis for use of platelet aggregation test, carbon 14- serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia

American Journal of Clinical Pathology

Volumn 111, Issue 5, 1999, Pages 700-706

  Pouplard, Claire ^a   Amiral, Jean ^b   Borg, Jeanne Yvonne ^c   Laporte Simitsidis, Silvy ^d   Delahousse, Bénédicte ^a   Gruel, Yves ^a  

^a SERVICE DE DERMATOLOGIE   (France)

^b Laboratoire Serbio   (France)

^c HÔPITAL CHARLES NICOLLE   (France)

^d University Jean Monnet of Saint Etienne EA3065   (France)

Author keywords

Heparin induced thrombocytopenia; Heparin platelet factor 4 enzyme linked immunosorbent assay; Platelet aggregation test; Serotonin release assay

Indexed keywords

ANTICOAGULANT AGENT; CARBON 14; HEPARIN; SEROTONIN; THROMBOCYTE FACTOR 4;

ARTICLE; DRUG INDUCED DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SEROTONIN RELEASE; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT; THROMBOCYTE DISORDER; THROMBOCYTOPENIA;

EID: 0032926268     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1093/ajcp/111.5.700     Document Type: Article

References (22)

1. Chong B. Heparin-induced thrombocytopenia. Br J Hoematol. 1995;89:431-439.
2. Warkentin TE, Kelton JG. A 14-year study of heparin-induced thrombocytopenia. Am J Med. 1996;101:502-507.
3. Warkentin T, Kelton J. Interaction of heparin with platelets, including heparin-induced thrombocytopenia. In: Bounameaux H, ed. Low-Molecular-Weight Heparins in Prophylaxis and Therapy of Thromboembolic Diseases. Vol 19. New York, NY: Marcel Dekker, 1994;75-127.
4. Gruel Y, Lang M, Damige L, et al. Fatal effect of re-exposure to heparin after previous heparin-associated thrombo-cytopenia and thrombosis. Lancet.1990;336:1077-1078.
5. Laster J, Elfrink R, Silver D. Reexposure to heparin of patients with heparin-associated antibodies. J Vasc Surg.1989;9:677-682.
6. Amiral J. Diagnostic tests in heparin-induced thrombocytopenia. Platelets. 1997;8:68-72.
7. Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost. 1993;69:344-350.
8. Pfueller S, David R. Different platelet specificities of heparin-dependent platelet aggregating factors in heparin-associated immune thrombocytopenia. Br J Haematol. 1986;64:149-159.
9. Warkentin T, Hayward C, Smith C, et al. Determinants of donor platelet variability when testing for heparin-induced thrombocytopenia. J Lab Clin Med. 1992;120:371-379.
10. Greinacher A, Michels I, Kiefel V, et al. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia. Thromb Haemost. 1991;66:734-736.
11. Sheridan D, Carter C, Kelton J. A diagnostic test for heparin-induced thrombocytopenia. Blood. 1986;67:27-30.
12. Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia. Thromb Haemost. 1992;68:95-96.
13. Amiral J, Bridey F, Wolf M, et al. Antibodies to macromolecular platelet factor 4-heparin complexes in heparin-induced thrombocytopenia: a study of 44 cases. Thromb Haemost. 1995;73:21-28.
14. Greinacher A, Amiral J, Dummel V, et al. Laboratory diagnosis of heparin-associated thrombocytopenia and comparison of platelet aggregation test, heparin-induced platelet activation test, and platelet factor 4/heparin enzyme-linked immunosorbent assay. Transfusion. 1994;34:381-385.
15. Arepally G, Reynolds C, Tomaski A, et al. Comparison of PF4/heparin ELISA assay with the C-14-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol. 1995;104:648-654.
16. Amiral J, Peynaud-Debayle E, Wolf M, et al. Generation of antibodies to heparin-PF4 complexes without thrombo-cytopenia in patients treated with unfractionated or low-molecular-weight heparin. Am J Hematol. 1996;52:90-95.
17. Pouplard C, Amiral J, Borg JY, et al. Differences in specificity of heparin-dependent antibodies developed in heparin-induced thrombocytopenia and consequences on cross-reactivity with danaparoid sodium. Br J Haematol. 1997;99:273-280.
18. Leroy J, Leclerc M, Delahousse B, et al. Treatment of heparin-associated thrombocytopenia and thrombosis with low molecular weight heparin (CY 216). Semin Thromb Hemost. 1985;11:326-329.
19. Ransonhoff D, Feinstein A. Problems of spectrum and bias in evaluating the efficacy of diagnostic tests. N Engl J Med. 1978;299:926-930.
20. Chong B, Castaldi P. Platelet proaggregating effect of heparin: possible mechanism for non-immune heparin associated thrombocytopenia. Aust NZ J Med. 1986;16:715-716.
21. Bauer TL, Arepally G, Konkle BA, et al. Prevalence of heparin-associated antibodies without thrombosis in patients undergoing cardiopulmonary bypass surgery. Circulation. 1997;95:1242-1246.
22. Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of autoantibodies to interleukin-8 or neutrophil-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood. 1996;88:410-416.